Q2 EPS Forecast for Edwards Lifesciences Cut by Analyst

Edwards Lifesciences Co. (NYSE:EW) – Equities research analysts at Zacks Research decreased their Q2 2025 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a note issued to investors on Tuesday, March 4th. Zacks Research analyst R. Department now expects that the medical research company will earn $0.60 per share for the quarter, down from their previous forecast of $0.62. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Zacks Research also issued estimates for Edwards Lifesciences’ Q3 2025 earnings at $0.60 EPS, Q4 2025 earnings at $0.62 EPS, Q1 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.69 EPS and FY2027 earnings at $3.07 EPS.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%.

Other equities research analysts have also recently issued reports about the company. Truist Financial reaffirmed a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Canaccord Genuity Group raised their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research report on Thursday, February 13th. Evercore ISI dropped their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday, February 12th. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Trading Up 2.1 %

EW stock opened at $72.89 on Wednesday. The business has a fifty day moving average price of $72.45 and a 200 day moving average price of $70.35. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock has a market capitalization of $42.99 billion, a price-to-earnings ratio of 10.46, a P/E/G ratio of 4.82 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in EW. Crowley Wealth Management Inc. acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth $26,000. Vega Investment Solutions bought a new stake in Edwards Lifesciences during the fourth quarter valued at $27,000. Millstone Evans Group LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences during the fourth quarter valued at $30,000. Finally, FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth about $30,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In related news, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now directly owns 60,372 shares in the company, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,739 shares of company stock worth $2,799,104 over the last quarter. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.